MENU
+Compare
YMAB
Stock ticker: NASDAQ
AS OF
Jun 13 closing price
Price
$4.71
Change
+$0.08 (+1.73%)
Capitalization
213.34M

YMAB Y-mAbs Therapeutics Forecast, Technical & Fundamental Analysis

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company... Show more

YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for YMAB with price predictions
Jun 13, 2025

YMAB's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for YMAB turned positive on May 16, 2025. Looking at past instances where YMAB's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Momentum Indicator moved above the 0 level on June 13, 2025. You may want to consider a long position or call options on YMAB as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

YMAB moved above its 50-day moving average on May 28, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for YMAB crossed bullishly above the 50-day moving average on June 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where YMAB advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 161 cases where YMAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for YMAB moved out of overbought territory on June 09, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where YMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

YMAB broke above its upper Bollinger Band on May 28, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.385) is normal, around the industry mean (16.954). P/E Ratio (0.000) is within average values for comparable stocks, (59.376). YMAB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.335). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (2.372) is also within normal values, averaging (257.043).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. YMAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

YMAB is expected to report earnings to rise 118.33% to -26 cents per share on August 07

Y-mAbs Therapeutics YMAB Stock Earnings Reports
Q2'25
Est.
$-0.26
Q1'25
Beat
by $0.07
Q4'24
Missed
by $0.03
Q3'24
Missed
by $0.01
Q2'24
Missed
by $0.09
The last earnings report on May 13 showed earnings per share of -11 cents, beating the estimate of -19 cents. With 472.81K shares outstanding, the current market capitalization sits at 213.34M.
A.I. Advisor
published General Information

General Information

a developer of novel antibody therapeutics for oncology targets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
230 Park Avenue
Phone
+1 646 885-8505
Employees
100
Web
https://www.ymabs.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AWTCX19.15-0.24
-1.24%
Virtus Duff & Phelps Water C
PRJCX38.69-0.61
-1.55%
PGIM Jennison Global Opportunities C
BMSRX14.02-0.23
-1.61%
MFS Blended Research Mid Cap Eq R1
MSCRX10.43-0.20
-1.88%
Madison Small Cap R6
RYWVX71.56-2.66
-3.58%
Rydex Emerging Markets 2X Strategy H

YMAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with ARWR. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
+1.73%
ARWR - YMAB
53%
Loosely correlated
-2.96%
CRSP - YMAB
50%
Loosely correlated
+0.19%
FATE - YMAB
49%
Loosely correlated
-8.93%
OCUL - YMAB
48%
Loosely correlated
-2.46%
RXRX - YMAB
47%
Loosely correlated
-4.84%
More